Aminoalkyl furan derivative

Claim 2

Form 2 ranitidine hydrochloride characterised by an infra-red spectrum as a mull in mineral oil showing the following main peaks: ______________________________________ 3260 1075 3190 1045 3100 1021 2560 1006 2510 991 2470 972 1620 958 1590 810 1570 800 1263 760 1230 700 1220 660 1195 640 1163 620 cm.sup.-1 1130 ______________________________________

Claim 3

Form 2 ranitidine hydrochloride according to claim 1 further characterised by the following x-ray powder diffraction pattern expressed in terms of "d" spacings and relative intensities (1) (s=strong, m=medium, w=weak, v=very, d=diffuse) and obtained by the Debye Scherrer method in a 114.6 mm diameter camera by exposure for 12 hours to CoK a radiation and for 3 hours to CuKa radiation: ______________________________________ d (Å) I d (Å) I ______________________________________ 10.73 m 3.40 2 w 6.50 3 vwd 3.35 2 vwd 6.13 m 3.25 wd 5.83 s 3.12 2 vw 5.63 3 vwd 3.04 2 vwd 5.42 s 2.97 3 vwd 5.06 2 vw 2.93 3 vwd 4.92 w 2.88 3 vwd 4.59 2 vw 2.81 vwd 4.40 s 2.72 vwd 4.28 w 2.66 3 vwd 3.91 wd 2.47 2 vwd 3.79 s 2.44 vw 3.71 m 2.34 2 vwd 3.60 vwd 2.30 3 vwd 3.46 m 2.21 2 vwd ______________________________________

Claim 4

A pharmaceutical composition in the form of tablets comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharamceutically acceptable carrier or diluent.

Claim 5

A pharmaceutical composition in the form of tablets comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 6

A pharmaceutical composition in the form of capsules comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 7

A pharmaceutical composition in the form of capsules comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 8

A pharmaceutical composition in the form of a powder comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 9

A pharmaceutical composition in the form of a powder comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 10

A pharamaceutical composition in the form of lozenges comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 11

A pharmaceutical composition in the form of lozenges comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 12

A pharmaceutical composition in the form of suppositories comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 13

A pharmaceutical composition in the form of suppositories comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 14

A pharmaceutical composition in the form of retention enemas comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 15

A pharmaceutical composition in the form of retention enemas comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 16

A pharmaceutical composition in the form of an ointment comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 17

A pharmaceutical composition in the form of an ointment comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

Claim 18

A method of treating condition mediated through histamine H 2 -receptors which comprises administering to a patient an effective amount of a compound as claimed in claim 1 to relieve said condition.

Claim 19

A method of treating condition mediated through histamine H 2 -receptors which comprises administering to a patient an effective amount of a compound as claimed in claim 2 to relieve said condition.